Currently, there are 117.85M common shares owned by the public and among those 104.34M shares have been available to trade.
The company’s stock has a 5-day price change of 14.19% and 28.58% over the past three months. ARQT shares are trading 17.88% year to date (YTD), with the 12-month market performance up to 48.46% higher. It has a 12-month low price of $6.99 and touched a high of $16.20 over the same period. ARQT has an average intraday trading volume of 2.22 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 18.41%, 20.61%, and 49.36% respectively.
Institutional ownership of Arcutis Biotherapeutics Inc (NASDAQ: ARQT) shares accounts for 101.79% of the company’s 117.85M shares outstanding.
It has a market capitalization of $1.95B and a beta (3y monthly) value of 1.72. The earnings-per-share (ttm) stands at -$1.16. Price movements for the stock have been influenced by the stock’s volatility, which stands at 10.82% over the week and 8.73% over the month.
Earnings per share for the fiscal year are expected to increase by 50.00%, and 150.99% over the next financial year.
Looking at the support for the ARQT, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on December 30, 2024, with the firm’s price target at $19. Jefferies coverage for the Arcutis Biotherapeutics Inc (ARQT) stock in a research note released on August 28, 2024 offered a Buy rating with a price target of $15. Mizuho was of a view on January 03, 2024 that the stock is Buy, while Mizuho gave the stock Neutral rating on October 26, 2023, issuing a price target of $57- $4. Goldman on their part issued Neutral rating on October 13, 2023.
